1-3 of 3
Jürgen Krauter, MD, Ph.D.
Close
Sort by
Journal Articles

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline

David A. Rizzieri, MD, Norbert Vey, MD, PhD, Xavier Thomas, MD, Françoise Huguet, Richard F Schlenk, MD, Jürgen Krauter, MD, Ph.D., Thomas Kindler, MD, Bjorn Gjertsen, MD, PhD, Igor W. Blau, Malin Johansen, Trygve Bergeland, Athos Gianella-Borradori, Tove Flem Jacobsen, Jianyu Rao, MD, Utz Krug
Journal: Blood
Blood (2012) 120 (21): 46.
https://doi.org/10.1182/blood.V120.21.46.46
Published: 2012
Journal Articles

The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients

Felicitas Thol, M.D., Michael Heuser, M.D., Claudia Winschel, Frederik Damm, MD, Katharina Wagner, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Gesine Bug, Oliver G. Ottmann, MD, PhD, Wolf-Karsten Hofmann, MD, Jürgen Krauter, MD, Ph.D., Arnold Ganser, MD
Journal: Blood
Blood (2011) 118 (21): 1734.
https://doi.org/10.1182/blood.V118.21.1734.1734
Published: 2011
Journal Articles

Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Christian Koenecke, MD, Philipp Kümpers, MD, Alexander Lukasz, Hartmut Hecker, MD, Elke Dammann, Willem Verhagen, MD, Sascha David, MD, Gudrun Göhring, MD, Stefanie Buchholz, MD, Eva Weissinger, MD, PhD, Jürgen Krauter, MD, Ph.D., Matthias Eder, MD, Ph.D., Hermann Haller, MD, Ph.D., Arnold Ganser, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3259.
https://doi.org/10.1182/blood.V112.11.3259.3259
Published: 2008